The effect of doxazosin withdrawal on normotensive subjects was examined by ambulatory blood pressure monitoring (ABPM) during twenty-four hours. Eight normotensive volunteers were treated with doxazosin for four weeks. ABPM was done the day before withdrawal and on the second and seventh days after withdrawal. The average systolic and diastolic BP were not altered by doxazosin withdrawal either on day 2 or day 7, but pulse rate (PR) decreased on day 2 and day 7. Daytime PR decreased on day 2, but both daytime and night time PR decreased on day 7. On withdrawal of doxazosin, the plasma nore pinephrine concentration decreased and the plasma renin activity tended to decrease. Neither overshooting hypertension nor cardiovascular event was re lated to doxazosin withdrawal was observed. It is concluded that, in normoten sive subjects, discontinuation of doxazosin may result in bradycardia without hypotension or signs of withdrawal syndrome.
Get full access to this article
View all access options for this article.
References
1.
1988Joint National Committee : The 1988 national report of the joint national committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med148:1023-1038, 1988.
2.
Fletcher AW, Franks PJ, Bulpitt CJ: The effect of withdrawing antihypertensive therapy: A review. J Hypertens6:431-436, 1988.
3.
Schmieder RE , Rockstroh JK, Messerli FJ: Antihypertensive therapy: To stop or not to stop. JAMA265: 1566-1571, 1991 .
4.
Finnerty FA Jr: Step-down therapy in hypertension. JAMA246:2593-2596, 1981.
5.
Langford HG, Blaufox D., Oberman A., et al: Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA235:657-664, 1985.
6.
MedicalResearch Council Working Party on Mild Hypertension: Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment . Br Med J293:988-992, 1986.
7.
Stamler R., Stamler J., Grimm R., et al: Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial—The hypertension control program . JAMA257:1484-1491, 1987 .
8.
Middeke M., Richter WO, Schwandt P., et al: Normalization of lipid metabolism after withdrawal from antihypertensive long-term therapy with beta blockers and diuretics. Arteriosclerosis10:145-147, 1990.
9.
Takata Y., Yoshizumi T., Ito Y., et al: Comparison of withdrawing antihypertensive therapy between diuretics and angiotensin converting enzyme inhibitors in essential hypertensives. Am Heart J124:1574-1580, 1992 .
10.
Pickering TG , Harshfield GA, Devereux RB, et al: What is the role of ambulatory blood pressure monitoring in the management of hypertensive patients?Hypertension7:171-177, 1985.
11.
O'Brien E., Cox JP, O'Malley K.: Ambulatory blood pressure measurement in the evaluation of blood pressure lowering drugs. J Hypertens7:243-247, 1989.
12.
Conway J., Johnston J., Coats A., et al: The use of ambulatory blood pressure monitoring to improve the accuracy and reduce the number of subjects in clinical trials of antihypertensive agents. J Hypertens6:111-116, 1988.
13.
Imai Y., Abe K., Sasaki S., et al: Determination of clinical accuracy and nocturnal blood pressure pattern by a new portable device for monitoring indirect ambulatory blood pressure. Am J Hypertens3:293-301, 1990.
14.
Alabaster VA , Davey MJ: The α1-adrenoceptor antagonist profile of doxazosin: Preclinical pharmacology. Br J Clin Pharmacol21:9s-17s, 1986.
15.
Taylor SH: Clinical pharmacotherapeutics of doxazosin. Am J Med87 (Suppl 2A):2s-10s, 1989.
16.
Cubeddu LX, Fuenmayor N., Caplan N., et al: Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther41:439-449, 1987.
17.
Shionoiri H. , Yasuda G., Yoshimura H., et al: Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol10:90-95, 1987.
18.
Whitworth JA , Butty J., Gordon D.: Acute haemodynamic and hormonal effects of oral doxazosin in normotensive subjects. Clin Exp Pharmacol Physiol14: 133-135, 1987.
19.
Houston MC: Abrupt cessation of treatment in hypertension: Consideration of clinical features, mechanisms, prevention, and management of the discontinuation syndrome . Am Heart J102:415-430, 1981.
20.
Pickering TG , James GD, Boddie C., et al: How common is white coat hypertension?JAMA259:225-228, 1988.
21.
White WB, Lund-Johansen P., McCabe EJ: Clinical evaluation of the Colin ABPM 630 at rest and during exercise: An ambulatory blood pressure monitor with gas-powered cuff inflation. J Hypertens7:477-483, 1989.
Elliott HL, Meredith PA, Reid JL: Pharmacokinetic overview of doxazosin. Am J Cardiol59:78G-81G, 1987.
24.
Donnelly R. , Elliott HL, Meredith PA, et al: Concentration-effect relationships and individual responses to doxazosin in essential hypertension . Br J Clin Pharmacol28:517-526, 1989.
25.
Oliver RM, Upward JW, Gewhurst AG, et al: The pharmacokinetics of doxazosin in patients with hypertension and renal impairment. Br J Clin Pharmacol29:417-422, 1990.
